Effects on Insulin Resistance With Tadalafil in Type 2 Diabetes - a Double-blind, Placebo-controlled Crossover Study

Inclusion Criteria: 1. T2D patient, previously diagnosed by fasting or 2-hr OGTT plasma glucose levels 2. Age females: 55-70 yrs (post-menopausal state defined as natural amenorrhea for at least 12 months); Age males: 40-70 yrs 3. BMI: 27-40 kg/m2 4. HbA1c \< 60 mmol/mol 5. Type 2 diabetes duration \> 3 months and \< 10 yrs 6. Understand and speak Swedish Exclusion Criteria: 1. Diabetes treatment with glitazones, GLP-1 analogues or DPP-IV inhibitors 2. Anti-hypertensive therapy with beta-blockers, ACE-inhibitors and/or angiotensin-II receptor blockers 3. Significant microvascular complications e.g. nephropathy (GFR\<60), proliferative retinopathy and symptomatic neuropathy e.g. postural hypotension 4. Previous significant vascular disease including angina pectoris and myocardial infarction, cerebral artery disease e.g. history of transient ischemic attacks and peripheral artery disease with no palpable pulses 5. Smoking \> 10 cig/day and/or smokeless tobacco \> one can per 2 days 6. Concurrent use of nitrates or NO donors, or an apparent risk that there may be a need of such medication 7. Cardiac failure (stages NYHA II-IV) 8. Uncontrolled hypertension \> 170/105 mm Hg 9. Apparent ECG-pathology indicating current or previous myocardial ischemia; 10. Males with erectile dysfunction 11. Hemophilia or a history of bruises or hepatic failure (\> 2-fold increase upper limit normal values of ASAT/ALAT) 12. Hypotension 13. Treatment with doxazosin 14. Anything in the contact with the patient that makes the doctor to believe that he/she will be uncompliant to the protocol.